Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting.

Domínguez-Ortega, Javier; Laorden, Daniel; Vílchez-Sánchez, Francisca; Bañas-Conejero, David; Quirce, Santiago

Domínguez-Ortega, Javier; Laorden, Daniel; Vílchez-Sánchez, Francisca; Bañas-Conejero, David; Quirce, Santiago.

Afiliação

Domínguez-Ortega J; Department of Allergy, Hospital Universitario La Paz, Institute for Health Research (IdiPAZ), Madrid, Spain.
Laorden D; Department of Pulmonology, Hospital Universitario La Paz, Madrid, Spain.
Vílchez-Sánchez F; Department of Allergy, Hospital Universitario La Paz, Institute for Health Research (IdiPAZ), Madrid, Spain.
Bañas-Conejero D; Medical Department, GSK, Madrid, Spain.
Quirce S; Department of Allergy, Hospital Universitario La Paz, Institute for Health Research (IdiPAZ), Madrid, Spain.

J Asthma ; 61(1): 39-47, 2024 01.

Article em En | MEDLINE | ID: mdl-37503953

Assuntos

Antiasmáticos; Asma; Eosinofilia Pulmonar; Humanos; Asma/terapia; Antiasmáticos/uso terapêutico; Análise Custo-Benefício; Qualidade de Vida; Estudos Retrospectivos

Palavras-chave

Treatment; economics; management/control

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Eosinofilia Pulmonar / Asma / Antiasmáticos Tipo de estudo: Health_economic_evaluation Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google